Skip to main content

Table 1 Characteristics of men that were included in the ED substudy by the 22 participating centres compared to those not included.

From: Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group

  Nonparticipants (n= 463) Participants (n= 130) P value
Age (years) 54.3 (46.0 to 64.1) 52.3 (45.1 to 61.5) 0.12
SSc duration by Raynaud's phenomenon (years) 6.4 (3.4 to 11.7) 7.0 (3.7 to 11.9) 0.21
SSc duration by first non-Raynaud's symptom (years) 5.4 (2.7 to 9.2) 6.0 (3.0 to 10.3) 0.20
Topoisomerase I (Scl70)-autoantibodiespositive 42.8 46.7 0.44
Anti-centromere autoantibodies-positive 14.9 15.7 0.82
U1RNP-positive 6.5 4.7 0.51
RNA polymerase III-positive 9.4 2.8 0.08
Diffuse SSc 56.8 63.7 0.18
Puffy hands 34.3 54.6 < 0.001*
mRSS 10 (4 to 16) 13 (6 to 20) 0.01*
mRSS > 20 16.8 25.0 0.05
C-reactive protein elevation 33.6 24.5 0.07
Digital ulcers 34.7 44.0 0.04*
Synovitis 13.1 20.0 0.05
Joint contractures 33.0 31.8 0.81
Tendon friction rubs 10.2 10.0 0.94
Muscle weakness 22.2 20.9 0.76
Muscle atrophy 11.1 15.5 0.17
Creatine kinase elevation 11.6 13.3 0.58
Oesophageal symptoms 54.4 60.4 0.23
Stomach symptoms 16.0 13.5 0.50
Intestinal symptoms 18.8 12.6 0.11
Lung fibrosis on chest X-ray or HRCT 60.4 56.7 0.59
Forced vital capacity (% predicted) 89 (75 to 101) 92 (81 to 103) 0.36
Forced vital capacity < 80% 32.2 23.3 0.10
DLCO (% predicted) 66 (49 to 82) 69 (55 to 88) 0.05
DLCO < 80% 71. 59.1 0.01*
PAPsys (mmHg) 30 (25 to 37) 27 (20 to 36) 0.004*
PAPsys > 40 mmHg 22.3 19.4 0.51
Diastolic dysfunction 20.4 18.8 0.70
Pericardial effusion 7.1 5.7 0.64
Left ventricular ejection fraction < 60% 25.1 20.0 0.31
Arterial hypertension 21.5 23.6 0.75
Renal crisis 3.3 4.5 0.50
Proteinuria 8.6 9.4 0.79
EULAR SSc activity score 1.5 (0.5 to 3.0) 2 (0.5 to 3.5) 0.27
High SSc activity (score ≥ 3) 27.2 35.2 0.19
Hypocomplementaemia 5.0 5.9 0.71
  1. Demographic parameters and disease characteristics from the EULAR Scleroderma Trial and Research database
  2. Data presented as median (interquartile range) or percentage. DLCO; diffusion capacity of the lung for carbon monoxide; HRCT, high resolution computed tomography; mRSS; modified Rodnan skin score; PAPsys; systolic pulmonary arterial pressure; SSc, systemic sclerosis. *Significant at P < 0.05.